Omeros Corporation (3O8.F)
- Previous Close
2.9860 - Open
2.9540 - Bid 2.8340 x 33800
- Ask 2.8940 x 33100
- Day's Range
2.8240 - 2.9540 - 52 Week Range
0.9770 - 7.0950 - Volume
2,000 - Avg. Volume
33 - Market Cap (intraday)
164.878M - Beta (5Y Monthly) 1.33
- PE Ratio (TTM)
-- - EPS (TTM)
-2.6200 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
34.63
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
www.omeros.comRecent News: 3O8.F
Performance Overview: 3O8.F
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 3O8.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 3O8.F
Valuation Measures
Market Cap
174.34M
Enterprise Value
234.90M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.64
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.22%
Return on Equity (ttm)
-576.33%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-174.92M
Diluted EPS (ttm)
-2.6200
Balance Sheet and Cash Flow
Total Cash (mrq)
171.85M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
95.59M